Pinochle, Carl? The letter Forest wrote to Icahn before the lawyers saw it
This article was originally published in Scrip
On 9 July 2012, Howard Solomon, the Chairman, Chief Executive Officer and President of Forest Laboratories, sent a public letter to activist investor Carl Icahn expressing his disappointment at Icahn's plans for the company (scripintelligence. com, 4 July 2012; scripintelligence. com, 3 July 2012).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.